Advertisement

Tumor Angiogenesis

Basic Mechanisms and Cancer Therapy

  • Dieter Marmé
  • Norbert Fusenig

Table of contents

  1. Front Matter
    Pages I-XVIII
  2. Historical Overview

    1. Front Matter
      Pages 1-1
  3. Mechanisms

    1. Front Matter
      Pages 29-29
    2. Anne Eichmann, Karine Bouvrée, Luc Pardanaud
      Pages 31-45
    3. Carmen Ruiz de Almodovar, Serena Zacchigna, Monica Autiero, Peter Carmeliet
      Pages 47-65
    4. Andreas Wicki, Gerhard Christofori
      Pages 67-88
    5. M. Christiane Brahimi-Horn, Julie Laferrière, Nathalie Mazure, Jacques Pouyssegur
      Pages 171-194
    6. Till Acker, Karl H. Plate
      Pages 195-214
    7. Malin Sund, Raghu Kalluri
      Pages 215-231
    8. Nathan V. Lee, M. Luisa Iruela-Arispe
      Pages 233-245
    9. Neta Ilan, Liat Fux, Michael Elkin, Israel Vlodavsky
      Pages 247-272
    10. Anne M. Goodwin, PatriciaA. D’Amore
      Pages 273-288
    11. Carmen Urbich, Emmanouil Chavakis, Stefanie Dimmeler
      Pages 309-324
    12. Marja Lohela, Kari Alitalo
      Pages 325-340
    13. Nicole Revencu, Laurence Boon, Miikka Vikkula
      Pages 363-374
  4. Animal Models and Preclinical Anti-Angiogenic Studies

    1. Front Matter
      Pages 375-375
    2. Hans-Peter Gerber, Megan E. Baldwin, Farbod Shojaei
      Pages 377-393
    3. Stephen R. Wedge, Juliane M. Jürgensmeier
      Pages 395-423
    4. Peter Bohlen, Zhenping Zhu, Daniel J. Hicklin
      Pages 425-452
    5. Paul E. Hughes, Anthony Polverino, Jonathan D. Oliner, Richard L. Kendall
      Pages 453-464
    6. Robert R. Langley, Sun-Jin Kim, Isaiah J. Fidler
      Pages 477-490
    7. Dragan Grabulovski, Dario Neri
      Pages 491-509
    8. James P. B. O’Connor, Daniela D. Rosa, Alan Jackson, Gordon C. Jayson
      Pages 511-528
    9. Fabian Kiessling, Martin Krix
      Pages 529-544
    10. Marcus Czabanka, Peter Vajkoczy
      Pages 545-555
    11. Peter Baluk, Beverly L. Falcón, Hiroya Hashizume, Barbara Sennino, Donald M. McDonald
      Pages 557-576
    12. Robert S. Kerbel, Urban Emmenegger, Shan Man, Raquel Munoz, Francesco Bertolini, Yuval Shared
      Pages 593-607
  5. Anti-Angiogenic Tumor Therapy in Clinical Studies

    1. Front Matter
      Pages 609-609
    2. Robert Mass
      Pages 611-653
    3. Joachim Drevs, Clemens Unger
      Pages 673-688
    4. Isan Chen, Carlo Bello, Zuleima Aguilar
      Pages 689-706
    5. Klaas Hoekman, Hester van Cruijsen, Giuseppe Giaccone
      Pages 707-715
    6. Bruno Morgan, Mark A. Horsfield
      Pages 717-739
    7. Thomas M. Moehler, Jens Hillengass, Axel Glasmacher, Hartmut Goldschmidt
      Pages 779-794
    8. Valentina Raia, Patrizia Mancuso, Francesco Bertolini
      Pages 795-808
    9. Gillian M. Tozer, Chryso Kanthou, David J. Chaplin
      Pages 809-829

About this book

Introduction

Preface Tumor development and progression occur as a result of cumulative acquisition of genetic alterations affecting oncogenes and tumor suppressor genes. As a consequence of these alterations the arising tumor gains some fatal properties such as increased cell proliferation and decreased apoptosis, resulting in a net accumulation of tra- formed cells. Once a critical volume is achieved, lack of oxygen and nutrients limits further growth. To overcome this obstacle, the tumor cells initiate a program focused on the formation of new blood vessels within the host tissue. This process is termed tumor angiogenesis and contributes to the progression of most solid tumors and the formation of metastases. Since its discovery more than 30 years ago by Dr. Judah Folkman, tumor angiog- esis has been proposed as an ideal target for novel tumor therapies. Today the first anti-angiogenic compounds are available for the treatment of patients but their s- cess in the clinic is rather limited when given as monotherapies. This is in contrast to many preclinical results which revealed a much higher efficacy of these therapeutics in appropriate animal models. The reasons for this discrepancy are manifold, one being the existence of more than one angiogenic signaling system capable of driving tumor angiogenesis. Therefore it is no surprise that the inhibition of just one system is not sufficient to block the formation of new blood vessels in patients.

Keywords

angiogenesis cancer cancer therapy cancer treatment chemotherapy clinical research drug drug development imaging inflammation pathophysiology physiology research tumor tumorigenesis

Editors and affiliations

  • Dieter Marmé
    • 1
  • Norbert Fusenig
    • 2
  1. 1.Klinik für TumorbiologieFreiburg i. Br.Germany
  2. 2.DKFZHeidelbergGermany

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-540-33177-3
  • Copyright Information Springer-Verlag Berlin Heidelberg 2008
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Medicine
  • Print ISBN 978-3-540-33176-6
  • Online ISBN 978-3-540-33177-3
  • Buy this book on publisher's site